Get the Stockscreener App
0.7381
0.22%
-0.0016
Pre-market:
.70
-0.0381
-5.16%
Mustang Bio Inc stock is traded at $0.7381, with a volume of 63,517.
It is down -0.22% in the last 24 hours and up +21.90% over the past month.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
See More
Previous Close:
$0.7397
Open:
$0.7281
24h Volume:
63,517
Relative Volume:
0.60
Market Cap:
$5.59M
Revenue:
-
Net Income/Loss:
$-2.72M
P/E Ratio:
-1.5374
EPS:
-0.4801
Net Cash Flow:
$-4.88M
1W Performance:
+5.43%
1M Performance:
+21.90%
6M Performance:
-34.68%
1Y Performance:
-36.91%
1-Day Range:
$0.6974
$0.7381
1-Week Range:
$0.68
$0.848
52-Week Range:
$0.5306
$7.00
Mustang Bio Inc Stock (MBIO) Company Profile
Name
Mustang Bio Inc
Sector
Industry
Phone
(781) 652-4500
Address
95 SAWYER RD, WALTHAM, NY
Compare MBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
0.7381 | 5.59M | 0 | -2.72M | -4.88M | -0.4801 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Oct-02-20 | Initiated | B. Riley FBR | Buy |
| Nov-20-19 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-19 | Initiated | H.C. Wainwright | Buy |
| Jun-21-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Initiated | Oppenheimer | Outperform |
View All
Mustang Bio Inc Stock (MBIO) Latest News
CNET Q3 2011 Earnings: EPS Misses by 65.4% Amid Uncertain Revenue DisclosureEarnings Growth Analysis - newsline.com
MBIO Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
ADXN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
CCL Q1 2026 Earnings: EPS Surpasses Estimates by 7.3%, Shares Gain 2.5%Cash Flow Report - newsline.com
MBIO Should I Buy - Intellectia AI
Spring Valley Acquisition Corp. III (SVAC) Holds Near Support Amid Modest DeclineRTH Profile - newsline.com
Mustang Bio (MBIO) Moves Higher, Testing Key Resistance at $0.83Analyst Downgrade Signals - newsline.com
Water Utility Fined £1.8 Million Over Parasite Outbreak in DevonProfit Announcement - newsline.com
JATT Price Today: JATT II Acquisition Corp. Stock Price, Quote & Chart | MEXC - MEXC
Mustang Bio Q4 2024 Earnings: Massive EPS Miss Highlights Cash Burn and Clinical Progress UncertaintyCapex Guidance - newsline.com
MSN Money - MSN
Mustang Bio (MBIO) Q4 2024 Earnings: Wider-Than-Expected Losses Offset by Positive Stock Movement Amid Pipeline FocusGuidance Accuracy Score - newsline.com
WaFd Inc. (WAFD) Q1 2026 Earnings: EPS Tops Estimates; Small Decline in StockFree Cash Flow Trends - The Legal Advocate
Real Asset Acquisition Corp. Unit (RAAQU) Holds Steady Near Support as Consolidation Phase ContinuesInvestment Factor - The Legal Advocate
Is Mustang Bio (MBIO) a Hidden Gem in the Microbiome Revolution, or a Risky Bet - Kavout
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageEarnings Miss Alert - newsline.com
Mustang Bio Inc. (MBIO) Gains 5.68% as Shares Approach Key Resistance at $0.70Merger Arbitrage - The Legal Advocate
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Severe EPS Miss Highlights Pre-Revenue Biotech Challenges - The Legal Advocate
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Massive EPS Miss Amidst No RevenueTangible Book Value - newsline.com
Mustang Bio (MBIO) Edges Higher: Biotech Stock Testing Key Resistance at $0.67Wyckoff Distribution - newsline.com
Varonis Systems (VRNS) Holds Steady Amid Minor Dip; Key Levels in FocusHull Moving Average - The Legal Advocate
SKYX Platforms Stock Slides: Support Test at $1.05 as Bearish Pressure MountsIV Rank - newsline.com
OSBC Q1 2026 Earnings: Earnings Miss Estimates Amid Narrowing MarginsTrough Earnings Signal - newsline.com
Universal Corporation (UVV) Q1 2026 Results Miss Estimates — EPS $1.32 vs $1.94Weak Earnings Momentum - The Legal Advocate
Mustang Bio (MBIO) Slides -1.27% as Selling Pressure Mounts 2026-05-18AI Expert Picks - Newser
What Mustang Bio (MBIO)'s -0.88% Decline Means for Investors 2026-05-18Stock Analysis Community - Newser
Mustang Bio stock (US62815P1003): restructuring progress keeps spotlight on cash and pipeline - AD HOC NEWS
Mustang Bio stock (US62815P1003): restructuring moves and Nasdaq relisting plan put focus back on ce - AD HOC NEWS
Brigade Enterprises FY26 Pre-Sales Dip 5% to Rs 7,424 Crore on Approval Delays; Board Recommends 1:3 Bonus IssueEarnings Outlook Update - The Legal Advocate
Mustang Bio’s Cancer Therapy Bets Face A Nasdaq Countdown - Finimize
TradingKey - TradingKey
Mustang Bio (NASDAQ: MBIO) reports Q1 loss, limited cash and Nasdaq bid-price risk - Stock Titan
Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
What Booz Allen (BAH) is doing to win in its industry | Q1 2026: EPS Tops ViewsConsensus Beat Rate - The Legal Advocate
SERA (Sera Prognostics) tops Q4 2025 EPS estimates, shares fall 2.51% on lack of revenue visibility.GAAP Earnings Report - The Legal Advocate
MUSTANG BIO, INC. (MBIO) - MSN
CAR-T Cell Therapy Market Will Generate Booming Growth Opportunities to 2030 | Novartis, Johnson & Johnson Services, Mustang, Sorrento Therapeutics, Fate Therapeutics etc. - industrytoday.co.uk
Mustang Bio Inc Stock (MBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):